MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today ...
REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ: REVB) is a potentially high-upside clinical-stage biotechnology company focused on immune modulation and inflammatory disease ...
The Hearty Soul on MSN
Body's most mysterious organ may play a key role in longevity and cancer
There is a small organ sitting behind your breastbone, roughly the size of a walnut in adults, that most physicians have ...
Living tissues do not change through biology alone. They are shaped by a constant dialogue among forces, chemicals, and ...
17h
Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin
Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data ReleaseHOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- ...
Cash and cash equivalents of $10.2 million as of March 31, 2026 Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC") ...
Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data Release HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or th ...
Creativity and curiosity have always been central to the work of Joshua Moreau, Ph.D., an immunologist whose work at Oregon ...
10h
Allergy treatment shifts toward precision medicine with tailored immunotherapy, new guidance shows
Until recently, allergy treatment was largely based on average treatment schemes. A patient with pollen allergy would receive ...
Organ transplantation remains the cornerstone treatment for end-stage organ failure. While conventional broad-spectrum immunosuppression effectively controls acute rejection, it fails to address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results